Ross, CA;
Aylward, EH;
Wild, EJ;
Langbehn, DR;
Long, JD;
Warner, JH;
Scahill, RI;
... Tabrizi, SJ; + view all
(2014)
Huntington disease: natural history, biomarkers and prospects for therapeutics.
Nature Reviews Neurology
, 10
204- 216.
10.1038/nrneurol.2014.24.
![[thumbnail of Tabrizi_Wild_1_2014_NRN_HD_DRAFT_CR-RLMS-ST-EW_EDITS__1-13_14_(2).pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
Tabrizi_Wild_1_2014_NRN_HD_DRAFT_CR-RLMS-ST-EW_EDITS__1-13_14_(2).pdf Download (481kB) |
Preview |
PDF
2013_NRN_Figure_1_10-11_13.pdf Download (22kB) |
Preview |
PDF
2013_NRN_Figure_2_Track_36_month_data.pdf Download (484kB) |
Preview |
PDF
2013_NRN_Figure_3_TRACK_CAP_graphs_EW_2013-04-18ai.pdf Download (1MB) |
Preview |
PDF
2013_NRN_Figure_4_CAP_Registry+COHORT_plots-4.pdf Download (297kB) |
Preview |
PDF
2013_NRN_Figure_5_Cell_Markers_EW_9-26-13.pdf Download (227kB) |
|
PDF
2013_NRN_Figure_6_Circuits_CR.pdf Download (38kB) |
Abstract
Huntington disease (HD) can be seen as a model neurodegenerative disorder, in that it is caused by a single genetic mutation and is amenable to predictive genetic testing, with estimation of years to predicted onset, enabling the entire range of disease natural history to be studied. Structural neuroimaging biomarkers show that progressive regional brain atrophy begins many years before the emergence of diagnosable signs and symptoms of HD, and continues steadily during the symptomatic or 'manifest' period. The continued development of functional, neurochemical and other biomarkers raises hopes that these biomarkers might be useful for future trials of disease-modifying therapeutics to delay the onset and slow the progression of HD. Such advances could herald a new era of personalized preventive therapeutics. We describe the natural history of HD, including the timing of emergence of motor, cognitive and emotional impairments, and the techniques that are used to assess these features. Building on this information, we review recent progress in the development of biomarkers for HD, and potential future roles of these biomarkers in clinical trials.
| Type: | Article |
|---|---|
| Title: | Huntington disease: natural history, biomarkers and prospects for therapeutics |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/nrneurol.2014.24 |
| Publisher version: | http://dx.doi.org/10.1038/nrneurol.2014.24 |
| Language: | English |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1422728 |
Archive Staff Only
 |
View Item |
